ImmunityBio's Potential Expansion in Japan Analyzed
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy IBRX?
Source: stocktwits
- Japan Market Expansion: Traders have outlined a hypothetical scenario where ImmunityBio could secure a 10% stake from a Japanese partner through a $10 billion investment, providing capital for future supply commitments and accelerating commercialization efforts in Japan.
- Stock Price Surge: ImmunityBio's shares (IBRX) have jumped over 6% this week amid speculation regarding a potential deal in Japan, with the stock price increasing over 200% in the past year, reflecting strong market optimism about the company's global expansion plans.
- Investor Focus on Japan Approval: Retail investors are highlighting Japan's Conditional Early Approval program as a potential catalyst for faster commercialization, particularly as drugs receiving this approval become eligible for National Health Insurance reimbursement, potentially turning Japan's 125 million population into a revenue-generating clinical trial.
- Ongoing FDA Scrutiny: Despite gaining regulatory traction overseas, ImmunityBio's Anktiva remains under heavy scrutiny from the FDA, which has flagged promotional claims, contrasting with the optimistic sentiment among traders regarding the company's international expansion efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.190
Low
5.00
Averages
7.33
High
9.00
Current: 8.190
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Potential Expansion in Japan Analyzed
- Japan Market Expansion: Traders have outlined a hypothetical scenario where ImmunityBio could secure a 10% stake from a Japanese partner through a $10 billion investment, providing capital for future supply commitments and accelerating commercialization efforts in Japan.
- Stock Price Surge: ImmunityBio's shares (IBRX) have jumped over 6% this week amid speculation regarding a potential deal in Japan, with the stock price increasing over 200% in the past year, reflecting strong market optimism about the company's global expansion plans.
- Investor Focus on Japan Approval: Retail investors are highlighting Japan's Conditional Early Approval program as a potential catalyst for faster commercialization, particularly as drugs receiving this approval become eligible for National Health Insurance reimbursement, potentially turning Japan's 125 million population into a revenue-generating clinical trial.
- Ongoing FDA Scrutiny: Despite gaining regulatory traction overseas, ImmunityBio's Anktiva remains under heavy scrutiny from the FDA, which has flagged promotional claims, contrasting with the optimistic sentiment among traders regarding the company's international expansion efforts.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that executives made false or misleading statements regarding Anktiva's capabilities during the class period, resulting in investor losses when the truth emerged, highlighting significant governance and disclosure failures within the company.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and achieved the largest settlement against a Chinese company in 2017, demonstrating its leadership and success in the field, urging investors to select experienced legal counsel.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of choosing the right representation in class actions to protect their interests.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19 and March 24, 2026, have until May 26, 2026, to apply as lead plaintiffs in a class action lawsuit alleging violations of the Securities Exchange Act of 1934 against the company and its executives.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements regarding its lead biologics product, Anktiva, asserting that it would allow all NMIBC patients to be cancer-free long-term, a claim that has not been substantiated.
- FDA Warning Letter Impact: A warning letter from the FDA, publicized on March 24, 2026, indicated that promotional materials misbranded Anktiva, violating the Federal Food, Drug, and Cosmetic Act, which contributed to a 21% drop in ImmunityBio's stock price.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP, a leading law firm in securities fraud litigation, recovered over $916 million for investors in 2025, highlighting its significant role in securities class action recoveries.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio faces a securities class action lawsuit after its Chief Scientific Officer claimed in a podcast that Anktiva could treat all cancers, leading to a 21% stock price drop on March 24, 2026, and nearly $2 billion in market cap loss, severely impacting investor confidence.
- FDA Warning Details: The FDA highlighted that ImmunityBio's promotional materials misleadingly suggested Anktiva could cure all cancers without sufficient efficacy data, posing a potential public health threat and exacerbating investor concerns about the company's future.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to file claims, reflecting a strong emphasis on corporate compliance and transparency.
- Market Reaction: This incident not only caused a significant stock price decline but also raised widespread doubts about ImmunityBio's future performance, potentially affecting its financing capabilities and competitive position in the market, increasing the legal risks faced by the company.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant failures in the company's disclosure practices.
- Investor Rights Protection: The firm encourages investors who purchased ImmunityBio securities during the class period to contact them by May 26, 2026, to participate in the lawsuit and seek compensation for losses, emphasizing the importance of protecting investor rights.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, and those who choose not to act will remain absent class members, underscoring the uncertainty of legal proceedings and potential risks for investors.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Promotional Material Issues: The FDA noted that ImmunityBio's TV ads and podcast misled the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, failing to provide sufficient data to support its efficacy claims, potentially leading to broader legal and regulatory challenges.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and encouraging witnesses to assist in the investigation, demonstrating a commitment to investor rights while reflecting potential deficiencies in the company's transparency and compliance.
See More
ImmunityBio's Potential Expansion in Japan Analyzed
- Japan Market Expansion: Traders have outlined a hypothetical scenario where ImmunityBio could secure a 10% stake from a Japanese partner through a $10 billion investment, providing capital for future supply commitments and accelerating commercialization efforts in Japan.
- Stock Price Surge: ImmunityBio's shares (IBRX) have jumped over 6% this week amid speculation regarding a potential deal in Japan, with the stock price increasing over 200% in the past year, reflecting strong market optimism about the company's global expansion plans.
- Investor Focus on Japan Approval: Retail investors are highlighting Japan's Conditional Early Approval program as a potential catalyst for faster commercialization, particularly as drugs receiving this approval become eligible for National Health Insurance reimbursement, potentially turning Japan's 125 million population into a revenue-generating clinical trial.
- Ongoing FDA Scrutiny: Despite gaining regulatory traction overseas, ImmunityBio's Anktiva remains under heavy scrutiny from the FDA, which has flagged promotional claims, contrasting with the optimistic sentiment among traders regarding the company's international expansion efforts.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that executives made false or misleading statements regarding Anktiva's capabilities during the class period, resulting in investor losses when the truth emerged, highlighting significant governance and disclosure failures within the company.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and achieved the largest settlement against a Chinese company in 2017, demonstrating its leadership and success in the field, urging investors to select experienced legal counsel.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of choosing the right representation in class actions to protect their interests.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19 and March 24, 2026, have until May 26, 2026, to apply as lead plaintiffs in a class action lawsuit alleging violations of the Securities Exchange Act of 1934 against the company and its executives.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements regarding its lead biologics product, Anktiva, asserting that it would allow all NMIBC patients to be cancer-free long-term, a claim that has not been substantiated.
- FDA Warning Letter Impact: A warning letter from the FDA, publicized on March 24, 2026, indicated that promotional materials misbranded Anktiva, violating the Federal Food, Drug, and Cosmetic Act, which contributed to a 21% drop in ImmunityBio's stock price.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP, a leading law firm in securities fraud litigation, recovered over $916 million for investors in 2025, highlighting its significant role in securities class action recoveries.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio faces a securities class action lawsuit after its Chief Scientific Officer claimed in a podcast that Anktiva could treat all cancers, leading to a 21% stock price drop on March 24, 2026, and nearly $2 billion in market cap loss, severely impacting investor confidence.
- FDA Warning Details: The FDA highlighted that ImmunityBio's promotional materials misleadingly suggested Anktiva could cure all cancers without sufficient efficacy data, posing a potential public health threat and exacerbating investor concerns about the company's future.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to file claims, reflecting a strong emphasis on corporate compliance and transparency.
- Market Reaction: This incident not only caused a significant stock price decline but also raised widespread doubts about ImmunityBio's future performance, potentially affecting its financing capabilities and competitive position in the market, increasing the legal risks faced by the company.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant failures in the company's disclosure practices.
- Investor Rights Protection: The firm encourages investors who purchased ImmunityBio securities during the class period to contact them by May 26, 2026, to participate in the lawsuit and seek compensation for losses, emphasizing the importance of protecting investor rights.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, and those who choose not to act will remain absent class members, underscoring the uncertainty of legal proceedings and potential risks for investors.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Promotional Material Issues: The FDA noted that ImmunityBio's TV ads and podcast misled the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, failing to provide sufficient data to support its efficacy claims, potentially leading to broader legal and regulatory challenges.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and encouraging witnesses to assist in the investigation, demonstrating a commitment to investor rights while reflecting potential deficiencies in the company's transparency and compliance.
See More
